Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer

Kochi, Mariko; Inomata, Takayuki; Niikura, Naoki; Masuda, Shinobu; Mizoo, Taeko; Nogami, Tomohiro; Shien, Tadahiko; Motoki, Takayuki; Taira, Naruto; Tokuda, Yutaka; Doihara, Hiroyoshi; Matsuoka, Junji; Fujiwara, Toshiyoshi

doi:10.1007/s10549-017-4502-3

Cited by 32 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next, 49 articles remained for full-text assessment due to 343 citations being excluded via title and abstract screening; of these, studies that were reviews (n = 2), inconsistent to the criteria of the high-level TILs in our study (n = 4), devoid of useful data (n = 16) and centered on PD-L1 + TILs (n = 3) or FOXP3+ TILs (n = 2) did not meet the inclusion criteria and hence were excluded. Ultimately, 22 qualified studies were included for meta-analysis (Table 1) [5,6,[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. The procedure of qualified article selection is outlined in Fig.…”

Section: Search Resultsmentioning

confidence: 99%

Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis

Wang

et al. 2020

BMC Women's Health

View full text Add to dashboard Cite

Background To investigate the impact of the elevation of tumor-infiltrating lymphocytes (TILs) in different molecular subtypes of primary breast cancer, i.e. each 10% increment of TILs and high-level TILs (TILs≥50%) in tumor, on overall survival (OS) and pathological complete response (pCR) and to compare the presentation of high-level TILs across these molecular subtypes. Methods Citation retrieval was performed in the PubMed, Cochrane Library, Embase and Web of Science databases. All statistical calculations were performed by the software of StataSE version 12.0. Results Twenty-two eligible clinical trials including 15,676 unique patients were included for meta-analysis. Each 10% increment of TILs significantly improved OS in human epidermal growth factor receptor 2 (HER2)-overexpression (pooled Hazard ratio (HR), 0.92; 95% CI, 0.89–0.95) and triple-negative (TN) (pooled HR, 0.90; 95% CI, 0.89–0.92) breast tumors but not in luminal tumor subtype (pooled HR, 1.06; 95% CI, 0.99–1.13). It was also associated with an increased pCR rate in breast cancers (pooled Odds ratio (OR), 1.27; 95% CI, 1.19–13.5). High-level TILs were significantly related with a higher pCR rate (pooled OR, 2.73; 95% CI, 2.40–3.01) than low-level TILs. The HER2-amplified (pooled OR, 3.14; 95% CI, 1.95–5.06) and TN (pooled OR, 4.09; 95% CI, 2.71–6.19) phenotypes of breast cancers expressed significantly more high-level TILs than the luminal tumor subtype, although the presentation of those between the former two subsets was not significantly different (pooled OR, 1.30; 95%CI, 0.83–2.04). Conclusions The elevation of TILs in breast tumors predicts favorable prognostic outcomes, particularly in the HER2-overexpression and TN subtypes.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis

Wang

et al. 2020

BMC Women's Health

View full text Add to dashboard Cite

show abstract

“…In particular, heightened immune function as reflected by the presence of tumor-infiltrating lymphocytes (TILs) is associated with lower mortality in patients with melanoma, 17 CRC, 18,19 bladder cancer, 20 and breast cancer, [21][22][23] and with favorable tumor features, such the absence of lymph node metastases in patients with melanoma 24 and chemotherapeutic response in individuals with breast cancer. 23,25,26 However, we are not aware of any data regarding the presence of TILs in tumors among transplant recipients. In addition, immunotherapy, in particular monoclonal antibodies that target programmed death-ligand 1 and its receptor programmed cell death protein 1 on T cells, is increasingly being used to manage patients with advanced stage cancers, including melanoma, bladder cancer, and lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Survival after a cancer diagnosis among solid organ transplant recipients in the United States

D’Arcy

Coghill

Lynch

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND: Transplant recipients have an elevated risk of cancer because of immunosuppressive medications used to prevent organ rejection, but to the authors' knowledge no study to date has comprehensively examined associations between transplantation status and mortality after a cancer diagnosis. METHODS: The authors assessed cases in the US general population (N=7,147,476) for 16 different cancer types as ascertained from 11 cancer registries. The presence of a solid organ transplant prior to diagnosis (N=11,416 cancer cases) was identified through linkage with the national transplantation registry . Cox models were used to examine the association between transplantation status and cancer-specific mortality, adjusting for demographic characteristics and cancer stage. RESULTS: For the majority of cancers, cancer-specific mortality was higher in transplant recipients compared with other patients with cancer. The increase was particularly pronounced for melanoma (adjusted hazard ratio [aHR], 2.59; 95% confidence interval [95% CI], 2.18-3.00) and cancers of the breast (aHR, 1.88; 95% CI, 1.61-2.19), bladder (aHR, 1.85; 95% CI, 1.58-2.17), and colorectum (aHR, 1.77; 95% CI, 1.60-1.96), but it also was increased for cancers of the oral cavity/pharynx, stomach, pancreas, kidney, and lung as well as diffuse large B-cell lymphoma (aHR range, 1.21-1.47). Associations remained significant after adjustment for first-course cancer treatment and generally were stronger among patients with local-stage cancers for whom potentially curative treatment was provided, including patients with melanoma (aHR, 3.82; 95% CI, 2.94-4.97) and cancers of the colorectum (aHR, 2.77; 95% CI, 2.07-3.70), breast (aHR, 2.08; 95% CI, 1.50-2.88), and prostate (aHR, 1.60; 95% CI, 1.12-2.29), despite the lack of an association for prostate cancer overall. CONCLUSIONS: For multiple cancer types, transplant recipients with cancer appear to have an elevated risk of dying of their cancer, even after adjustment for stage and treatment, which may be due to impaired immunity. Cancer 2019;125:933-942.

show abstract

“…Several independent studies (2, 4-6) meanwhile have also shown an association between patient survival and treatment response with an increased density of tumor-infiltrating lymphocytes (TIL) in diverse solid tumor types. In addition, there is substantial evidence supporting the fact that increased TIL density is associated with better chemotherapeutic response (7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer

Corredor

Wang

Zhou

et al. 2019

Clinical Cancer Research

189

169

View full text Add to dashboard Cite

show abstract

Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer

Cited by 32 publications

References 42 publications

Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis

Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis

Survival after a cancer diagnosis among solid organ transplant recipients in the United States

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer

Contact Info

Product

Resources

About